Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Raibizumab Biosimilars Market Research Report 2025

Global Raibizumab Biosimilars Market Research Report 2025

Industry: Pharma & Healthcare

Published Date: 2025-01-16

Pages: 126 Pages

Report ld: 3456256

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Raibizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Raibizumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Raibizumab Biosimilars.

The Raibizumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Raibizumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Raibizumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

Roche

Novartis

Genentech

Pfizer

Sartorius

Eli Lilly

Bayer

Amgen

PlantForm

PharmaPraxis

Samsung Bioepis

Centus

Cadila Pharmaceuticals

Dr Reddy's

Aurobindo Pharma

Biocad

MAbxience

Hetero

Biocon

Kirin Biologics

Mylan

BeiGene

Innovent

Qilu Pharmaceutical

Hengrui Pharmaceuticals

Hisun Pharmaceutical

TOT BIOPHARM

Luye Pharmaceutical

Henlius

Segment by Type

AMD

CNV

DME

Segment by Application

ARMD

Diabetic Retinopathy

Macular Edema

Consumption by Region

North America

U.S.

Canada

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Europe

Germany

France

U.K.

Italy

Russia

Latin America

Mexico

Brazil

Argentina

Middle East and Africa

Turkey

Saudi Arabia

U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Raibizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Raibizumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Raibizumab Biosimilars Market Overview

1.1 Product Definition

1.2 Raibizumab Biosimilars by Type

1.2.1 Global Raibizumab Biosimilars Market Value Comparison by Type (2024 VS 2031)

1.2.2 AMD

1.2.3 CNV

1.2.4 DME

1.3 Raibizumab Biosimilars by Application

1.3.1 Global Raibizumab Biosimilars Market Value by Application (2024 VS 2031)

1.3.2 ARMD

1.3.3 Diabetic Retinopathy

1.3.4 Macular Edema

1.4 Global Raibizumab Biosimilars Market Size Estimates and Forecasts

1.4.1 Global Raibizumab Biosimilars Revenue 2020-2031

1.4.2 Global Raibizumab Biosimilars Sales 2020-2031

1.4.3 Global Raibizumab Biosimilars Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Raibizumab Biosimilars Market Competition by Manufacturers

2.1 Global Raibizumab Biosimilars Sales Market Share by Manufacturers (2020-2025)

2.2 Global Raibizumab Biosimilars Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Raibizumab Biosimilars Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Raibizumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Raibizumab Biosimilars, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Raibizumab Biosimilars, Product Type & Application

2.7 Global Key Manufacturers of Raibizumab Biosimilars, Date of Enter into This Industry

2.8 Global Raibizumab Biosimilars Market Competitive Situation and Trends

2.8.1 Global Raibizumab Biosimilars Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Raibizumab Biosimilars Players Market Share by Revenue

2.8.3 Global Raibizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Raibizumab Biosimilars Market Scenario by Region

3.1 Global Raibizumab Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Raibizumab Biosimilars Sales by Region: 2020-2031

3.2.1 Global Raibizumab Biosimilars Sales by Region: 2020-2025

3.2.2 Global Raibizumab Biosimilars Sales by Region: 2026-2031

3.3 Global Raibizumab Biosimilars Revenue by Region: 2020-2031

3.3.1 Global Raibizumab Biosimilars Revenue by Region: 2020-2025

3.3.2 Global Raibizumab Biosimilars Revenue by Region: 2026-2031

3.4 North America Raibizumab Biosimilars Market Facts & Figures by Country

3.4.1 North America Raibizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Raibizumab Biosimilars Sales by Country (2020-2031)

3.4.3 North America Raibizumab Biosimilars Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Raibizumab Biosimilars Market Facts & Figures by Country

3.5.1 Europe Raibizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Raibizumab Biosimilars Sales by Country (2020-2031)

3.5.3 Europe Raibizumab Biosimilars Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Raibizumab Biosimilars Market Facts & Figures by Region

3.6.1 Asia Pacific Raibizumab Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Raibizumab Biosimilars Sales by Region (2020-2031)

3.6.3 Asia Pacific Raibizumab Biosimilars Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Raibizumab Biosimilars Market Facts & Figures by Country

3.7.1 Latin America Raibizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Raibizumab Biosimilars Sales by Country (2020-2031)

3.7.3 Latin America Raibizumab Biosimilars Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Raibizumab Biosimilars Market Facts & Figures by Country

3.8.1 Middle East and Africa Raibizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Raibizumab Biosimilars Sales by Country (2020-2031)

3.8.3 Middle East and Africa Raibizumab Biosimilars Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Raibizumab Biosimilars Sales by Type (2020-2031)

4.1.1 Global Raibizumab Biosimilars Sales by Type (2020-2025)

4.1.2 Global Raibizumab Biosimilars Sales by Type (2026-2031)

4.1.3 Global Raibizumab Biosimilars Sales Market Share by Type (2020-2031)

4.2 Global Raibizumab Biosimilars Revenue by Type (2020-2031)

4.2.1 Global Raibizumab Biosimilars Revenue by Type (2020-2025)

4.2.2 Global Raibizumab Biosimilars Revenue by Type (2026-2031)

4.2.3 Global Raibizumab Biosimilars Revenue Market Share by Type (2020-2031)

4.3 Global Raibizumab Biosimilars Price by Type (2020-2031)

5 Segment by Application

5.1 Global Raibizumab Biosimilars Sales by Application (2020-2031)

5.1.1 Global Raibizumab Biosimilars Sales by Application (2020-2025)

5.1.2 Global Raibizumab Biosimilars Sales by Application (2026-2031)

5.1.3 Global Raibizumab Biosimilars Sales Market Share by Application (2020-2031)

5.2 Global Raibizumab Biosimilars Revenue by Application (2020-2031)

5.2.1 Global Raibizumab Biosimilars Revenue by Application (2020-2025)

5.2.2 Global Raibizumab Biosimilars Revenue by Application (2026-2031)

5.2.3 Global Raibizumab Biosimilars Revenue Market Share by Application (2020-2031)

5.3 Global Raibizumab Biosimilars Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Roche Raibizumab Biosimilars Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Novartis Raibizumab Biosimilars Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Genentech

6.3.1 Genentech Company Information

6.3.2 Genentech Description and Business Overview

6.3.3 Genentech Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Genentech Raibizumab Biosimilars Product Portfolio

6.3.5 Genentech Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Company Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Pfizer Raibizumab Biosimilars Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 Sartorius

6.5.1 Sartorius Company Information

6.5.2 Sartorius Description and Business Overview

6.5.3 Sartorius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Sartorius Raibizumab Biosimilars Product Portfolio

6.5.5 Sartorius Recent Developments/Updates

6.6 Eli Lilly

6.6.1 Eli Lilly Company Information

6.6.2 Eli Lilly Description and Business Overview

6.6.3 Eli Lilly Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Eli Lilly Raibizumab Biosimilars Product Portfolio

6.6.5 Eli Lilly Recent Developments/Updates

6.7 Bayer

6.7.1 Bayer Company Information

6.7.2 Bayer Description and Business Overview

6.7.3 Bayer Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Bayer Raibizumab Biosimilars Product Portfolio

6.7.5 Bayer Recent Developments/Updates

6.8 Amgen

6.8.1 Amgen Company Information

6.8.2 Amgen Description and Business Overview

6.8.3 Amgen Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Amgen Raibizumab Biosimilars Product Portfolio

6.8.5 Amgen Recent Developments/Updates

6.9 PlantForm

6.9.1 PlantForm Company Information

6.9.2 PlantForm Description and Business Overview

6.9.3 PlantForm Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.9.4 PlantForm Raibizumab Biosimilars Product Portfolio

6.9.5 PlantForm Recent Developments/Updates

6.10 PharmaPraxis

6.10.1 PharmaPraxis Company Information

6.10.2 PharmaPraxis Description and Business Overview

6.10.3 PharmaPraxis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.10.4 PharmaPraxis Raibizumab Biosimilars Product Portfolio

6.10.5 PharmaPraxis Recent Developments/Updates

6.11 Samsung Bioepis

6.11.1 Samsung Bioepis Company Information

6.11.2 Samsung Bioepis Description and Business Overview

6.11.3 Samsung Bioepis Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Samsung Bioepis Raibizumab Biosimilars Product Portfolio

6.11.5 Samsung Bioepis Recent Developments/Updates

6.12 Centus

6.12.1 Centus Company Information

6.12.2 Centus Description and Business Overview

6.12.3 Centus Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Centus Raibizumab Biosimilars Product Portfolio

6.12.5 Centus Recent Developments/Updates

6.13 Cadila Pharmaceuticals

6.13.1 Cadila Pharmaceuticals Company Information

6.13.2 Cadila Pharmaceuticals Description and Business Overview

6.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Product Portfolio

6.13.5 Cadila Pharmaceuticals Recent Developments/Updates

6.14 Dr Reddy's

6.14.1 Dr Reddy's Company Information

6.14.2 Dr Reddy's Description and Business Overview

6.14.3 Dr Reddy's Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Dr Reddy's Raibizumab Biosimilars Product Portfolio

6.14.5 Dr Reddy's Recent Developments/Updates

6.15 Aurobindo Pharma

6.15.1 Aurobindo Pharma Company Information

6.15.2 Aurobindo Pharma Description and Business Overview

6.15.3 Aurobindo Pharma Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.15.4 Aurobindo Pharma Raibizumab Biosimilars Product Portfolio

6.15.5 Aurobindo Pharma Recent Developments/Updates

6.16 Biocad

6.16.1 Biocad Company Information

6.16.2 Biocad Description and Business Overview

6.16.3 Biocad Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.16.4 Biocad Raibizumab Biosimilars Product Portfolio

6.16.5 Biocad Recent Developments/Updates

6.17 MAbxience

6.17.1 MAbxience Company Information

6.17.2 MAbxience Description and Business Overview

6.17.3 MAbxience Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.17.4 MAbxience Raibizumab Biosimilars Product Portfolio

6.17.5 MAbxience Recent Developments/Updates

6.18 Hetero

6.18.1 Hetero Company Information

6.18.2 Hetero Description and Business Overview

6.18.3 Hetero Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.18.4 Hetero Raibizumab Biosimilars Product Portfolio

6.18.5 Hetero Recent Developments/Updates

6.19 Biocon

6.19.1 Biocon Company Information

6.19.2 Biocon Description and Business Overview

6.19.3 Biocon Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.19.4 Biocon Raibizumab Biosimilars Product Portfolio

6.19.5 Biocon Recent Developments/Updates

6.20 Kirin Biologics

6.20.1 Kirin Biologics Company Information

6.20.2 Kirin Biologics Description and Business Overview

6.20.3 Kirin Biologics Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.20.4 Kirin Biologics Raibizumab Biosimilars Product Portfolio

6.20.5 Kirin Biologics Recent Developments/Updates

6.21 Mylan

6.21.1 Mylan Company Information

6.21.2 Mylan Description and Business Overview

6.21.3 Mylan Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.21.4 Mylan Raibizumab Biosimilars Product Portfolio

6.21.5 Mylan Recent Developments/Updates

6.22 BeiGene

6.22.1 BeiGene Company Information

6.22.2 BeiGene Description and Business Overview

6.22.3 BeiGene Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.22.4 BeiGene Raibizumab Biosimilars Product Portfolio

6.22.5 BeiGene Recent Developments/Updates

6.23 Innovent

6.23.1 Innovent Company Information

6.23.2 Innovent Description and Business Overview

6.23.3 Innovent Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.23.4 Innovent Raibizumab Biosimilars Product Portfolio

6.23.5 Innovent Recent Developments/Updates

6.24 Qilu Pharmaceutical

6.24.1 Qilu Pharmaceutical Company Information

6.24.2 Qilu Pharmaceutical Description and Business Overview

6.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Product Portfolio

6.24.5 Qilu Pharmaceutical Recent Developments/Updates

6.25 Hengrui Pharmaceuticals

6.25.1 Hengrui Pharmaceuticals Company Information

6.25.2 Hengrui Pharmaceuticals Description and Business Overview

6.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Product Portfolio

6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates

6.26 Hisun Pharmaceutical

6.26.1 Hisun Pharmaceutical Company Information

6.26.2 Hisun Pharmaceutical Description and Business Overview

6.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Product Portfolio

6.26.5 Hisun Pharmaceutical Recent Developments/Updates

6.27 TOT BIOPHARM

6.27.1 TOT BIOPHARM Company Information

6.27.2 TOT BIOPHARM Description and Business Overview

6.27.3 TOT BIOPHARM Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.27.4 TOT BIOPHARM Raibizumab Biosimilars Product Portfolio

6.27.5 TOT BIOPHARM Recent Developments/Updates

6.28 Luye Pharmaceutical

6.28.1 Luye Pharmaceutical Company Information

6.28.2 Luye Pharmaceutical Description and Business Overview

6.28.3 Luye Pharmaceutical Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.28.4 Luye Pharmaceutical Raibizumab Biosimilars Product Portfolio

6.28.5 Luye Pharmaceutical Recent Developments/Updates

6.29 Henlius

6.29.1 Henlius Company Information

6.29.2 Henlius Description and Business Overview

6.29.3 Henlius Raibizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.29.4 Henlius Raibizumab Biosimilars Product Portfolio

6.29.5 Henlius Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Raibizumab Biosimilars Industry Chain Analysis

7.2 Raibizumab Biosimilars Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Raibizumab Biosimilars Production Mode & Process Analysis

7.4 Raibizumab Biosimilars Sales and Marketing

7.4.1 Raibizumab Biosimilars Sales Channels

7.4.2 Raibizumab Biosimilars Distributors

7.5 Raibizumab Biosimilars Customer Analysis

8 Raibizumab Biosimilars Market Dynamics

8.1 Raibizumab Biosimilars Industry Trends

8.2 Raibizumab Biosimilars Market Drivers

8.3 Raibizumab Biosimilars Market Challenges

8.4 Raibizumab Biosimilars Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Raibizumab Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Raibizumab Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Raibizumab Biosimilars Market Competitive Situation by Manufacturers in 2024

Table 4. Global Raibizumab Biosimilars Sales (Units) of Key Manufacturers (2020-2025)

Table 5. Global Raibizumab Biosimilars Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Raibizumab Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Raibizumab Biosimilars Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Raibizumab Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Raibizumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Raibizumab Biosimilars, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Raibizumab Biosimilars, Product Type & Application

Table 12. Global Key Manufacturers of Raibizumab Biosimilars, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Raibizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Raibizumab Biosimilars as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Raibizumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Raibizumab Biosimilars Sales by Region (2020-2025) & (Units)

Table 18. Global Raibizumab Biosimilars Sales Market Share by Region (2020-2025)

Table 19. Global Raibizumab Biosimilars Sales by Region (2026-2031) & (Units)

Table 20. Global Raibizumab Biosimilars Sales Market Share by Region (2026-2031)

Table 21. Global Raibizumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Raibizumab Biosimilars Revenue Market Share by Region (2020-2025)

Table 23. Global Raibizumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Raibizumab Biosimilars Revenue Market Share by Region (2026-2031)

Table 25. North America Raibizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Raibizumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 27. North America Raibizumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 28. North America Raibizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Raibizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Raibizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Raibizumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 32. Europe Raibizumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 33. Europe Raibizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Raibizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Raibizumab Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Raibizumab Biosimilars Sales by Region (2020-2025) & (Units)

Table 37. Asia Pacific Raibizumab Biosimilars Sales by Region (2026-2031) & (Units)

Table 38. Asia Pacific Raibizumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Raibizumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Raibizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Raibizumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 42. Latin America Raibizumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 43. Latin America Raibizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Raibizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Raibizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Raibizumab Biosimilars Sales by Country (2020-2025) & (Units)

Table 47. Middle East and Africa Raibizumab Biosimilars Sales by Country (2026-2031) & (Units)

Table 48. Middle East and Africa Raibizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Raibizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Raibizumab Biosimilars Sales (Units) by Type (2020-2025)

Table 51. Global Raibizumab Biosimilars Sales (Units) by Type (2026-2031)

Table 52. Global Raibizumab Biosimilars Sales Market Share by Type (2020-2025)

Table 53. Global Raibizumab Biosimilars Sales Market Share by Type (2026-2031)

Table 54. Global Raibizumab Biosimilars Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Raibizumab Biosimilars Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Raibizumab Biosimilars Revenue Market Share by Type (2020-2025)

Table 57. Global Raibizumab Biosimilars Revenue Market Share by Type (2026-2031)

Table 58. Global Raibizumab Biosimilars Price (K USD/Unit) by Type (2020-2025)

Table 59. Global Raibizumab Biosimilars Price (K USD/Unit) by Type (2026-2031)

Table 60. Global Raibizumab Biosimilars Sales (Units) by Application (2020-2025)

Table 61. Global Raibizumab Biosimilars Sales (Units) by Application (2026-2031)

Table 62. Global Raibizumab Biosimilars Sales Market Share by Application (2020-2025)

Table 63. Global Raibizumab Biosimilars Sales Market Share by Application (2026-2031)

Table 64. Global Raibizumab Biosimilars Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Raibizumab Biosimilars Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Raibizumab Biosimilars Revenue Market Share by Application (2020-2025)

Table 67. Global Raibizumab Biosimilars Revenue Market Share by Application (2026-2031)

Table 68. Global Raibizumab Biosimilars Price (K USD/Unit) by Application (2020-2025)

Table 69. Global Raibizumab Biosimilars Price (K USD/Unit) by Application (2026-2031)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 73. Roche Raibizumab Biosimilars Product

Table 74. Roche Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 78. Novartis Raibizumab Biosimilars Product

Table 79. Novartis Recent Developments/Updates

Table 80. Genentech Company Information

Table 81. Genentech Description and Business Overview

Table 82. Genentech Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 83. Genentech Raibizumab Biosimilars Product

Table 84. Genentech Recent Developments/Updates

Table 85. Pfizer Company Information

Table 86. Pfizer Description and Business Overview

Table 87. Pfizer Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 88. Pfizer Raibizumab Biosimilars Product

Table 89. Pfizer Recent Developments/Updates

Table 90. Sartorius Company Information

Table 91. Sartorius Description and Business Overview

Table 92. Sartorius Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 93. Sartorius Raibizumab Biosimilars Product

Table 94. Sartorius Recent Developments/Updates

Table 95. Eli Lilly Company Information

Table 96. Eli Lilly Description and Business Overview

Table 97. Eli Lilly Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 98. Eli Lilly Raibizumab Biosimilars Product

Table 99. Eli Lilly Recent Developments/Updates

Table 100. Bayer Company Information

Table 101. Bayer Description and Business Overview

Table 102. Bayer Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 103. Bayer Raibizumab Biosimilars Product

Table 104. Bayer Recent Developments/Updates

Table 105. Amgen Company Information

Table 106. Amgen Description and Business Overview

Table 107. Amgen Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 108. Amgen Raibizumab Biosimilars Product

Table 109. Amgen Recent Developments/Updates

Table 110. PlantForm Company Information

Table 111. PlantForm Description and Business Overview

Table 112. PlantForm Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 113. PlantForm Raibizumab Biosimilars Product

Table 114. PlantForm Recent Developments/Updates

Table 115. PharmaPraxis Company Information

Table 116. PharmaPraxis Description and Business Overview

Table 117. PharmaPraxis Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 118. PharmaPraxis Raibizumab Biosimilars Product

Table 119. PharmaPraxis Recent Developments/Updates

Table 120. Samsung Bioepis Company Information

Table 121. Samsung Bioepis Description and Business Overview

Table 122. Samsung Bioepis Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 123. Samsung Bioepis Raibizumab Biosimilars Product

Table 124. Samsung Bioepis Recent Developments/Updates

Table 125. Centus Company Information

Table 126. Centus Description and Business Overview

Table 127. Centus Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 128. Centus Raibizumab Biosimilars Product

Table 129. Centus Recent Developments/Updates

Table 130. Cadila Pharmaceuticals Company Information

Table 131. Cadila Pharmaceuticals Description and Business Overview

Table 132. Cadila Pharmaceuticals Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 133. Cadila Pharmaceuticals Raibizumab Biosimilars Product

Table 134. Cadila Pharmaceuticals Recent Developments/Updates

Table 135. Dr Reddy's Company Information

Table 136. Dr Reddy's Description and Business Overview

Table 137. Dr Reddy's Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 138. Dr Reddy's Raibizumab Biosimilars Product

Table 139. Dr Reddy's Recent Developments/Updates

Table 140. Aurobindo Pharma Company Information

Table 141. Aurobindo Pharma Description and Business Overview

Table 142. Aurobindo Pharma Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 143. Aurobindo Pharma Raibizumab Biosimilars Product

Table 144. Aurobindo Pharma Recent Developments/Updates

Table 145. Biocad Company Information

Table 146. Biocad Description and Business Overview

Table 147. Biocad Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 148. Biocad Raibizumab Biosimilars Product

Table 149. Biocad Recent Developments/Updates

Table 150. MAbxience Company Information

Table 151. MAbxience Description and Business Overview

Table 152. MAbxience Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 153. MAbxience Raibizumab Biosimilars Product

Table 154. MAbxience Recent Developments/Updates

Table 155. Hetero Company Information

Table 156. Hetero Description and Business Overview

Table 157. Hetero Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 158. Hetero Raibizumab Biosimilars Product

Table 159. Hetero Recent Developments/Updates

Table 160. Biocon Company Information

Table 161. Biocon Description and Business Overview

Table 162. Biocon Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 163. Biocon Raibizumab Biosimilars Product

Table 164. Biocon Recent Developments/Updates

Table 165. Kirin Biologics Company Information

Table 166. Kirin Biologics Description and Business Overview

Table 167. Kirin Biologics Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 168. Kirin Biologics Raibizumab Biosimilars Product

Table 169. Kirin Biologics Recent Developments/Updates

Table 170. Mylan Company Information

Table 171. Mylan Description and Business Overview

Table 172. Mylan Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 173. Mylan Raibizumab Biosimilars Product

Table 174. Mylan Recent Developments/Updates

Table 175. BeiGene Company Information

Table 176. BeiGene Description and Business Overview

Table 177. BeiGene Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 178. BeiGene Raibizumab Biosimilars Product

Table 179. BeiGene Recent Developments/Updates

Table 180. Innovent Company Information

Table 181. Innovent Description and Business Overview

Table 182. Innovent Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 183. Innovent Raibizumab Biosimilars Product

Table 184. Innovent Recent Developments/Updates

Table 185. Qilu Pharmaceutical Company Information

Table 186. Qilu Pharmaceutical Description and Business Overview

Table 187. Qilu Pharmaceutical Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 188. Qilu Pharmaceutical Raibizumab Biosimilars Product

Table 189. Qilu Pharmaceutical Recent Developments/Updates

Table 190. Hengrui Pharmaceuticals Company Information

Table 191. Hengrui Pharmaceuticals Description and Business Overview

Table 192. Hengrui Pharmaceuticals Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 193. Hengrui Pharmaceuticals Raibizumab Biosimilars Product

Table 194. Hengrui Pharmaceuticals Recent Developments/Updates

Table 195. Hisun Pharmaceutical Company Information

Table 196. Hisun Pharmaceutical Description and Business Overview

Table 197. Hisun Pharmaceutical Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 198. Hisun Pharmaceutical Raibizumab Biosimilars Product

Table 199. Hisun Pharmaceutical Recent Developments/Updates

Table 200. TOT BIOPHARM Company Information

Table 201. TOT BIOPHARM Description and Business Overview

Table 202. TOT BIOPHARM Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 203. TOT BIOPHARM Raibizumab Biosimilars Product

Table 204. TOT BIOPHARM Recent Developments/Updates

Table 205. Luye Pharmaceutical Company Information

Table 206. Luye Pharmaceutical Description and Business Overview

Table 207. Luye Pharmaceutical Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 208. Luye Pharmaceutical Raibizumab Biosimilars Product

Table 209. Luye Pharmaceutical Recent Developments/Updates

Table 210. Henlius Company Information

Table 211. Henlius Description and Business Overview

Table 212. Henlius Raibizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2020-2025)

Table 213. Henlius Raibizumab Biosimilars Product

Table 214. Henlius Recent Developments/Updates

Table 215. Key Raw Materials Lists

Table 216. Raw Materials Key Suppliers Lists

Table 217. Raibizumab Biosimilars Distributors List

Table 218. Raibizumab Biosimilars Customers List

Table 219. Raibizumab Biosimilars Market Trends

Table 220. Raibizumab Biosimilars Market Drivers

Table 221. Raibizumab Biosimilars Market Challenges

Table 222. Raibizumab Biosimilars Market Restraints

Table 223. Research Programs/Design for This Report

Table 224. Key Data Information from Secondary Sources

Table 225. Key Data Information from Primary Sources

Table 226. Authors List of This Report

List of Figures

Figure 1. Product Picture of Raibizumab Biosimilars

Figure 2. Global Raibizumab Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Raibizumab Biosimilars Market Share by Type: 2024 & 2031

Figure 4. AMD Product Picture

Figure 5. CNV Product Picture

Figure 6. DME Product Picture

Figure 7. Global Raibizumab Biosimilars Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Raibizumab Biosimilars Market Share by Application: 2024 & 2031

Figure 9. ARMD

Figure 10. Diabetic Retinopathy

Figure 11. Macular Edema

Figure 12. Global Raibizumab Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Raibizumab Biosimilars Market Size (2020-2031) & (US$ Million)

Figure 14. Global Raibizumab Biosimilars Sales (2020-2031) & (Units)

Figure 15. Global Raibizumab Biosimilars Average Price (K USD/Unit) & (2020-2031)

Figure 16. Raibizumab Biosimilars Report Years Considered

Figure 17. Raibizumab Biosimilars Sales Share by Manufacturers in 2024

Figure 18. Global Raibizumab Biosimilars Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Raibizumab Biosimilars Players: Market Share by Revenue in Raibizumab Biosimilars in 2024

Figure 20. Raibizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Raibizumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Raibizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 23. North America Raibizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Raibizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 27. Europe Raibizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 28. Germany Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Raibizumab Biosimilars Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Raibizumab Biosimilars Revenue Market Share by Region (2020-2031)

Figure 35. China Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Taiwan Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Philippines Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Raibizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 46. Latin America Raibizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Raibizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Raibizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. U.A.E Raibizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Raibizumab Biosimilars by Type (2020-2031)

Figure 56. Global Revenue Market Share of Raibizumab Biosimilars by Type (2020-2031)

Figure 57. Global Raibizumab Biosimilars Price (K USD/Unit) by Type (2020-2031)

Figure 58. Global Sales Market Share of Raibizumab Biosimilars by Application (2020-2031)

Figure 59. Global Revenue Market Share of Raibizumab Biosimilars by Application (2020-2031)

Figure 60. Global Raibizumab Biosimilars Price (K USD/Unit) by Application (2020-2031)

Figure 61. Raibizumab Biosimilars Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Raibizumab Biosimilars market? zhanKai

The top companies in the global Raibizumab Biosimilars market are Roche、Novartis、Genentech.

Related Reports

Raibizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 181
USD 3950.00
(Single User License)
Global Raibizumab Biosimilars Market Research Report 2024
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published Date: 2024-01-20
Pages: 112
USD 2900.00
(Single User License)
Raibizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published Date: 2024-01-11
Pages: 165
USD 3950.00
(Single User License)

Raibizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Raibizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 181
USD 3950.00 (Single User License)
Global Raibizumab Biosimilars Market Research Report 2024
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published: 2024-01-20
Pages: 112
USD 2900.00 (Single User License)
Raibizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
Published: 2024-01-11
Pages: 165
USD 3950.00 (Single User License)